Gene: FGF8

2253
AIGF|FGF-8|HBGF-8|HH6|KAL6
fibroblast growth factor 8
protein-coding
10q24.32
Ensembl:ENSG00000107831 MIM:600483 Vega:OTTHUMG00000018940 UniprotKB:P55075
NG_007151.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.960e-1 (AD)  3.954e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
B4GALNT30.6
IFITM100.581
ZFR20.569
RTBDN0.569
OGFR0.567
EMX10.564
SRRM30.563
PDZD70.559
MLXIPL0.557
FSD10.556

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SNX18-0.391
HEATR5A-0.379
ZNF501-0.376
YES1-0.374
CCDC121-0.373
PARD3B-0.372
PDE3A-0.364
PDLIM5-0.359
NXT2-0.358
CDCA7L-0.357

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C5130035-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione"5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of FGF8 mRNA"17409431
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
D000079AcetaldehydeAcetaldehyde affects the expression of FGF8 mRNA22634333
D003913DextroamphetamineDextroamphetamine results in increased expression of FGF8 mRNA12205029
D003913DextroamphetamineSOD1 inhibits the reaction [Dextroamphetamine results in increased expression of FGF8 mRNA]12205029
D000728AndrogensAndrogens results in increased expression of FGF8 protein12404063
D000728AndrogensAndrogens results in increased expression of FGF812779088
D004958Estradiol[BMP15 protein co-treated with GDF9 protein] promotes the reaction [FGF8 protein inhibits the reaction [FSHB protein results in increased abundance of Estradiol]]22366471
D004958EstradiolGDF9 protein promotes the reaction [FGF8 protein inhibits the reaction [FSHB protein results in increased abundance of Estradiol]]22366471
D004958EstradiolFGF8 protein inhibits the reaction [FSHB protein results in increased abundance of Estradiol]22366471
C452139BIRB 796BIRB 796 results in decreased expression of FGF8 mRNA24303162
C551172bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)"bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV) results in increased expression of FGF8 mRNA"20162321
C006780bisphenol Abisphenol A results in decreased expression of FGF8 mRNA22718145
C006780bisphenol Abisphenol A results in decreased expression of FGF8 mRNA25181051
D002066BusulfanBusulfan results in decreased expression of FGF8 mRNA15786497
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of FGF817707671
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of FGF8 mRNA26272509
C007076citralcitral results in decreased expression of FGF8 mRNA15581867
D005576ColforsinColforsin results in increased activity of FGF8 protein15193767
D003907DexamethasoneDexamethasone results in decreased expression of FGF8 mRNA28453788
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of FGF8 mRNA19464577|2227372
D004041Dietary FatsDietary Fats results in increased expression of FGF8 mRNA25016146
C118739entinostatentinostat results in decreased expression of FGF8 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
D000431EthanolEthanol results in decreased expression of FGF8 mRNA15108242
D005419FlavonoidsFlavonoids results in decreased expression of FGF8 mRNA18035473
C061365flusilazoleflusilazole affects the expression of FGF8 mRNA22634333
D005485FlutamideFlutamide inhibits the reaction [Testosterone results in increased expression of FGF8 mRNA]16723184
D005492Folic AcidFolic Acid inhibits the reaction [[GLI3 gene mutant form co-treated with ochratoxin A] results in increased expression of FGF8 mRNA]17688467
D005839GentamicinsGentamicins results in decreased expression of FGF8 mRNA22061828
D006493HeparinHeparin binds to and results in increased activity of FGF8 protein alternative form12077148
D006497Heparitin SulfateHeparitin Sulfate binds to FGF8 protein alternative form15769253
D006497Heparitin SulfateHeparitin Sulfate analog results in increased activity of FGF8 protein12460940
D006497Heparitin SulfateHeparitin Sulfate analog binds to and results in increased activity of FGF8 protein alternative form12077148
D006497Heparitin SulfateHeparitin Sulfate analog binds to FGF8 protein14707131
C409722hexaconazolehexaconazole results in decreased expression of FGF8 mRNA22045034
D008727MethotrexateMethotrexate results in decreased expression of FGF8 mRNA17400583
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FGF8 mRNA21385734
C004925methylmercuric chloridemethylmercuric chloride affects the expression of FGF8 mRNA20864626
C028577monobutyl phthalatemonobutyl phthalate affects the expression of FGF8 mRNA19162170
D009151Mustard GasIL10 protein affects the reaction [Mustard Gas affects the expression of FGF8 mRNA]16173061
C025589ochratoxin AFolic Acid inhibits the reaction [[GLI3 gene mutant form co-treated with ochratoxin A] results in increased expression of FGF8 mRNA]17688467
C025589ochratoxin A[GLI3 gene mutant form co-treated with ochratoxin A] results in increased expression of FGF8 mRNA17688467
C025589ochratoxin Aochratoxin A promotes the reaction [GLI3 gene mutant form results in increased expression of FGF8 protein]16922921
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of FGF8 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of FGF8 mRNA26272509
C029217phenyl-N-tert-butylnitronephenyl-N-tert-butylnitrone inhibits the reaction [Thalidomide results in decreased expression of FGF8 mRNA]12242718
D010795Phthalic AcidsPhthalic Acids results in increased expression of FGF8 mRNA22112501
D010936Plant ExtractsPlant Extracts results in decreased expression of FGF8 mRNA23557933
C045362prochlorazprochloraz results in decreased expression of FGF8 mRNA21470553
C105686SU 5402SU 5402 results in decreased activity of FGF8 protein12618132
D013739TestosteroneAR protein promotes the reaction [Testosterone results in increased expression of FGF8 protein]12140757
D013739TestosteroneFlutamide inhibits the reaction [Testosterone results in increased expression of FGF8 mRNA]16723184
D013739TestosteroneTestosterone results in increased expression of FGF8 mRNA16723184
D013739TestosteroneTestosterone results in increased expression of FGF8 protein12140757
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of FGF8 mRNA21296121
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FGF8 mRNA21570461
D013792Thalidomidephenyl-N-tert-butylnitrone inhibits the reaction [Thalidomide results in decreased expression of FGF8 mRNA]12242718
D013792ThalidomideThalidomide results in decreased expression of FGF8 mRNA12242718|1471333
D014212TretinoinTretinoin results in increased expression of FGF8 protein16316642
D014212TretinoinTretinoin results in decreased expression of FGF8 mRNA14527434
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of GFRA1 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of GLI1 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NEFL protein17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NEFM protein17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NR4A2 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NTRK1 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NTRK2 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of NTRK3 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of PTCH1 mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of RBFOX3 protein17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of SYP protein17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of TH mRNA17085092
D014212Tretinoin[Tretinoin co-treated with SHH protein co-treated with FGF8 protein] results in increased expression of TH protein17085092
D014212TretinoinTretinoin results in decreased expression of FGF8 mRNA21934132
D014212TretinoinCYP26A1 protein inhibits the reaction [Tretinoin results in decreased expression of FGF8 mRNA]12588859
D014212TretinoinTretinoin results in decreased expression of FGF8 mRNA12588859|1462395
D014212TretinoinTretinoin results in decreased expression of FGF8 protein17551590
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of FGF8 mRNA24935251|2627250
D014635Valproic AcidValproic Acid affects the expression of FGF8 mRNA25979313|2607246
D014635Valproic AcidValproic Acid results in decreased expression of FGF8 mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of FGF8 mRNA24935251
D014635Valproic AcidValproic Acid results in increased methylation of FGF8 gene29154799
D014635Valproic AcidValproic Acid affects the expression of FGF8 mRNA26072468|2769348
D014635Valproic AcidValproic Acid promotes the reaction [GLI3 gene mutant form affects the expression of FGF8 mRNA]16359493
D014635Valproic AcidValproic Acid results in decreased expression of FGF8 mRNA22045034
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of FGF8 gene25560391
D002762CholecalciferolCholecalciferol results in decreased expression of FGF8 mRNA16508948

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005104fibroblast growth factor receptor binding-IEA-  
GO:0008083growth factor activity-IEA-  
GO:00163031-phosphatidylinositol-3-kinase activity-TAS-  
GO:0042056chemoattractant activity-IEA-  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0001569branching involved in blood vessel morphogenesis-IEA-  
GO:0001656metanephros development-IEP18437684  
GO:0001658branching involved in ureteric bud morphogenesis-IEA-  
GO:0001759organ induction-IEA-  
GO:0001823mesonephros development-IEP18437684  
GO:0001839neural plate morphogenesis-IEA-  
GO:0001947heart looping-IEA-  
GO:0001974blood vessel remodeling-IEA-  
GO:0003148outflow tract septum morphogenesis-ISS-  
GO:0003198epithelial to mesenchymal transition involved in endocardial cushion formation-ISS-  
GO:0006915apoptotic process-IEA-  
GO:0006979response to oxidative stress-IEA-  
GO:0007369gastrulation-NAS8700553  
GO:0008045motor neuron axon guidance-IEA-  
GO:0008078mesodermal cell migration-IEA-  
GO:0008284positive regulation of cell proliferation-IEA-  
GO:0008406gonad development-IMP18596921  
GO:0008543fibroblast growth factor receptor signaling pathway-IGI8663044  
GO:0008543fibroblast growth factor receptor signaling pathway-TAS22235191  
GO:0009653anatomical structure morphogenesis-NAS8595889  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0010628positive regulation of gene expression-TAS24431302  
GO:0014070response to organic cyclic compound-IEA-  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0021543pallium development-IEA-  
GO:0021544subpallium development-IEA-  
GO:0021798forebrain dorsal/ventral pattern formation-IEA-  
GO:0021846cell proliferation in forebrain-IEA-  
GO:0021884forebrain neuron development-IEA-  
GO:0023019signal transduction involved in regulation of gene expression-IEA-  
GO:0030509BMP signaling pathway-IEA-  
GO:0030539male genitalia development-IEA-  
GO:0030878thyroid gland development-IEA-  
GO:0030916otic vesicle formation-IEA-  
GO:0030917midbrain-hindbrain boundary development-IEA-  
GO:0033563dorsal/ventral axon guidance-IEA-  
GO:0035116embryonic hindlimb morphogenesis-IEA-  
GO:0035909aorta morphogenesis-IEA-  
GO:0036092phosphatidylinositol-3-phosphate biosynthetic process-IEA-  
GO:0042476odontogenesis-IEP17394220  
GO:0042487regulation of odontogenesis of dentin-containing tooth-IEA-  
GO:0042493response to drug-IEA-  
GO:0043524negative regulation of neuron apoptotic process-IEA-  
GO:0045165cell fate commitment-IEA-  
GO:0045597positive regulation of cell differentiation-TAS22235191  
GO:0045840positive regulation of mitotic nuclear division-IEA-  
GO:0046622positive regulation of organ growth-IEA-  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0048853forebrain morphogenesis-IEA-  
GO:0050918positive chemotaxis-IEA-  
GO:0051781positive regulation of cell division-IEA-  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0055026negative regulation of cardiac muscle tissue development-IMP20702560  
GO:0060037pharyngeal system development-IEA-  
GO:0060070canonical Wnt signaling pathway-IEA-  
GO:0060128corticotropin hormone secreting cell differentiation-IEA-  
GO:0060129thyroid-stimulating hormone-secreting cell differentiation-IEA-  
GO:0060348bone development-IMP18596921  
GO:0060425lung morphogenesis-IEA-  
GO:0060445branching involved in salivary gland morphogenesis-IEA-  
GO:0060563neuroepithelial cell differentiation-IDA17309880  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IEA-  
GO:0071542dopaminergic neuron differentiation-IDA15193767  
GO:0071542dopaminergic neuron differentiation-TAS24431302  
GO:0090134cell migration involved in mesendoderm migration-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005622intracellular-IEA-  
GO:0009897external side of plasma membrane-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04810Regulation of actin cytoskeleton
hsa05200Pathways in cancer
hsa05218Melanoma
Reactome ID Reactome Term Evidence
R-HSA-109704PI3K CascadeTAS
R-HSA-112399IRS-mediated signallingTAS
R-HSA-1226099Signaling by FGFR in diseaseTAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-1643685DiseaseTAS
R-HSA-1839122Signaling by activated point mutants of FGFR1TAS
R-HSA-1839124FGFR1 mutant receptor activationTAS
R-HSA-1839126FGFR2 mutant receptor activationTAS
R-HSA-1839130Signaling by activated point mutants of FGFR3TAS
R-HSA-190236Signaling by FGFRTAS
R-HSA-190239FGFR3 ligand binding and activationTAS
R-HSA-190241FGFR2 ligand binding and activationTAS
R-HSA-190242FGFR1 ligand binding and activationTAS
R-HSA-190322FGFR4 ligand binding and activationTAS
R-HSA-190371FGFR3b ligand binding and activationTAS
R-HSA-190372FGFR3c ligand binding and activationTAS
R-HSA-190373FGFR1c ligand binding and activationTAS
R-HSA-190375FGFR2c ligand binding and activationTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2033514FGFR3 mutant receptor activationTAS
R-HSA-2033519Activated point mutants of FGFR2TAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-2404192Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)TAS
R-HSA-2428924IGF1R signaling cascadeTAS
R-HSA-2428928IRS-related events triggered by IGF1RTAS
R-HSA-5654219Phospholipase C-mediated cascade: FGFR1TAS
R-HSA-5654221Phospholipase C-mediated cascade; FGFR2TAS
R-HSA-5654227Phospholipase C-mediated cascade; FGFR3TAS
R-HSA-5654228Phospholipase C-mediated cascade; FGFR4TAS
R-HSA-5654687Downstream signaling of activated FGFR1TAS
R-HSA-5654688SHC-mediated cascade:FGFR1TAS
R-HSA-5654689PI-3K cascade:FGFR1TAS
R-HSA-5654693FRS-mediated FGFR1 signalingTAS
R-HSA-5654695PI-3K cascade:FGFR2TAS
R-HSA-5654696Downstream signaling of activated FGFR2TAS
R-HSA-5654699SHC-mediated cascade:FGFR2TAS
R-HSA-5654700FRS-mediated FGFR2 signalingTAS
R-HSA-5654704SHC-mediated cascade:FGFR3TAS
R-HSA-5654706FRS-mediated FGFR3 signalingTAS
R-HSA-5654708Downstream signaling of activated FGFR3TAS
R-HSA-5654710PI-3K cascade:FGFR3TAS
R-HSA-5654712FRS-mediated FGFR4 signalingTAS
R-HSA-5654716Downstream signaling of activated FGFR4TAS
R-HSA-5654719SHC-mediated cascade:FGFR4TAS
R-HSA-5654720PI-3K cascade:FGFR4TAS
R-HSA-5654726Negative regulation of FGFR1 signalingTAS
R-HSA-5654727Negative regulation of FGFR2 signalingTAS
R-HSA-5654732Negative regulation of FGFR3 signalingTAS
R-HSA-5654733Negative regulation of FGFR4 signalingTAS
R-HSA-5654736Signaling by FGFR1TAS
R-HSA-5654738Signaling by FGFR2TAS
R-HSA-5654741Signaling by FGFR3TAS
R-HSA-5654743Signaling by FGFR4TAS
R-HSA-5655253Signaling by FGFR2 in diseaseTAS
R-HSA-5655302Signaling by FGFR1 in diseaseTAS
R-HSA-5655332Signaling by FGFR3 in diseaseTAS
R-HSA-5658623FGFRL1 modulation of FGFR1 signalingTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-74751Insulin receptor signalling cascadeTAS
R-HSA-74752Signaling by Insulin receptorTAS
R-HSA-8853338Signaling by FGFR3 point mutants in cancerTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28880263LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. (2017 Sep 7)Yuan YCell Death Dis